Длительный устойчивый смешанный химеризм у пациента с синдромом Вискотта–Олдрича после аллогенной трансплантации гемопоэтических стволовых клеток

В статье представлено клиническое наблюдение пациента с синдромом Вискотта–Олдрича, у которого после трансплантации гемопоэтических стволовых клеток (ТГСК) от гаплоидентичного донора определялась длительная персистенция смешанного химеризма. На основании анализа клинической картины пациента после ТГСК было показано, что для коррекции тромбоцитопении необходимо присутствие > 50% донорских клеток в миелоидной линии. Кроме того, наличие смешанного химеризма в В-лимфоцитах внесло свой вклад в развитие аутоиммунных осложнений у пациента, а также к стойкой гипогаммаглобулинемии, несмотря на восстановление нормального числа лимфоцитов всех популяций. Роль смешанного химеризма в патогенезе иммунных посттрансплантационных осложнений требует изучения на больших группах пациентов с первичными иммунодефицитами. Родители пациента дали согласие на использование информации, в том числе фотографий ребенка, в научных исследованиях и публикациях.

1. Ochs H.D., Rosen F.S. The Wiskott–Aldrich syndrome. In: Ochs H.D., Smith C.I.E., Puck J.M., eds. Primary Immune Deficiency Diseases: A Molecular and Genetic Approach. New York, NY: Oxford University Press; 2007. Рр. 454–469.

2. Buchbinder D., Nugent D.J., Fillipovich A.H. Wiskott–Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet 2014; 7: 55–66.

3. Derry J.M., Ochs H.D., Francke U. Isolation of a novel gene mutated in Wiskott–Aldrich syndrome. Cell 1994; 78: 635–44.

4. Zhu Q., Zhang M., Blaese R.M., Derry J.M., Junker A., Francke U., et al. The Wiskott_Aldrich Syndrome and X LInked Congenital Thrombocytopenia are caused by mutations in the same gene. Blood 1995; 86 (10): 3797–804.

5. Blundell M.P., Worth A., Bouma G., Thrasher A.J. The Wiskott–Aldrich syndrome: The actin cytoskeleton and immune cell function. Disease Markers 2010; 29 (3–4): 157–75.

6. Bouma G., Burns S.O., Thrasher A.J. Wiskott–Aldrich syndrome: immunodeficiency resulting from defective cell migration and impaired immunostimulatory activation. Immunobiology 2009; 214 (9): 778–90.

7. Ochs H.D., Filipovich A.H., Veys P., Cowan M.J., Kapoor N. Wiskott–Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant 2009; 15 (1): 84–90.

8. Chiang S.C.C., Vergamini S.M., Husami A., Neumeier L., Quinn K., Ellerhorst T., et al. Screening for Wiskott–Aldrich syndrome by flow cytometry. J Allergy Clin Immunol 2018; 142 (1): 333–5.

9. Nakajima M., Yamada M., Yamaguchi K., Sakiyama Y., Oda A., Nelson D.L., et al. Possible application of flow cytometry for evaluation of the structure and functional status of WASP in peripheral blood mononuclear cells; European J Haematol 2009; 82 (3): 223–30.

10. Першин Д.Е., Лодоева О.Б., Фадеева М.С., Мерсиянова И.В., Хорева А.Л., Владимиров И.С. и др. Разработка метода диагностики синдрома Вискотта–Олдрича путем оценки экспрессии белка WASP с использованием проточной цитофлуориметрии. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2020; 19 (2): 141–51.

11. Bach F.H., Albertini R.J., Joo P., Anderson J.L., Bortin M.M. Bone-marrow transplantation in a patient with the Wiskott–Aldrich syndrome. Lancet 1968; 292 (7583): 1364–6.

12. Balashov D., Laberko A., Shcherbina A., Trakhtman P., Abramov D., Gutovskaya E., et al. Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCRab+ and CD19+ Cell-Depleted Stem Cell Transplantation in Patients with Wiskott–Aldrich Syndrome. Biol Blood Marrow Transplant 2018; 24 (7): 1432–40.

13. Elfeky R.A., Furtado-Silva J.M., Chiesa R. One hundred percent survival after transplantation of 34 patients with Wiskott–Aldrich syndrome over 20 years. J Allergy Clin Immunol 2018; 142: 1654–6.

14. Burroughs L., Petrovic A., Brazauskas R., Liu X., Griffith L.M., Ochs H.D., et al. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood 2020; 135: 2094–105.

15. Ozsahin H., Cavazzana-Calvo M., Notarangelo L.D., Schulz А., Thrasher A.J., Mazzolari Е., et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott–Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008; 111 (1): 439–45.

16. Moratto D., Giliani S., Bonfim C., Mazzolari E., Fischer A., Ochs H.D., et al. Long-term outcome and lineage-specific chimerism in 194 patients with WiskottAldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 2011; 118: 1675–84.

17. Zimmerman C., Shenoy S. Chimerism in the Realm of Hematopoietic Stem Cell Transplantation for Non-malignant Disorders – A Perspective. Front Immunol 2020; 11: 1791. DOI: 10.3389/fimmu.2020.01791

18. Navarro-Bailón A., Carbonell D., Escudero A., Chicano M., Muñiz P., SuárezGonzález J., et al. Short Tandem Repeats (STRs) as Biomarkers for the Quantitative Follow-Up of Chimerism after Stem Cell Transplantation: Methodological Considerations and Clinical Application. Genes (Basel) 2020; 11 (9): 993.

19. Baron F., Little M.T., Storb R. Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reducedintensity or nonmyeloablative conditioning. Blood Rev 2005; 19: 153–64.

20. Sugita J., Tanaka J., Hashimoto A., Shiratori S., Yasumoto А., Wakasa К., et al. Influence of conditioning regimens and stem cell sources on donor-type chimerism early after stem cell transplantation. Ann Hematol 2008; 87: 1003–8.

21. Bader P., Niethammer D., Willasch A., Kreyenberg H., Klingebiel T. How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant 2005; 35 (2): 107–19.

22. Hartz B., Marsh R., Rao K., Henter J.-I., Jordan M., Filipovich L., et al. The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. Blood 2016; 127 (25): 3281–90.

23. Morillo-Gutierrez B., Beier R., Rao K., Burroughs L., Schulz A., Ewins A.-M., et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood 2016; 128 (3): 440–8.

24. Abd Hamid I.J., Slatter M.A., McKendrick F., Pearce M.S., Gennery A.R. Longterm outcome of hematopoietic stem cell transplantation for IL2RG/JAK3 SCID: a cohort report. Blood 2017; 129 (15): 2198–201.

25. Lum S.H., Elfeky R., Achini F.R., Margarit-Soler А., Cinicola В., Perez-Heras I., еt al. Outcome of Non-hematological Autoimmunity After Hematopoietic Cell Transplantation in Children with Primary Immunodeficiency. J Clin Immunol 2021; 41: 171–84.

26. Laberko A., Sultanova E., Gutovskaya E., Shipitsina I., Shelikhova L., Kurnikova Е., et al. Mismatched related versus matched unrelated donors in TCRalphabeta/CD19-depleted HSCT for primary immunodeficiencies. Blood 2019; 134 (20): 1755–63.

27. Rao K., Adams S., Qasim W., Allwood Z., Worth A., Silva J., et al. Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen. J Allergy Clin Immunol 2016; 138: 1152–60.

28. Marsh R.A., Rao M.B., Gefen A., Bellman D., Mehta P.A., Khandelwal P., et al. Experience with alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning hematopoietic cell transplantation in patients with nonmalignant diseases reveals good outcomes and that the risk of mixed chimerism depends on underlying disease, stem cell source, and alemtuzumab regimen. Biol Blood Marrow Transplant 2015; 21: 1460–70. DOI: 10.1016/j.bbmt.2015.04.009

29. Sullivan K.E., Mullen C.A., Blaese R.M., Winkelstein J.A. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994; 125:876–85. DOI: 10.1016/S0022-3476(05)82002-5

30. Catucci M., Castiello M.C., Pala F., Bosticardo M., Villa A. Autoimmunity in Wiskott–Aldrich syndrome: an unsolved enigma. Front Immunol 2012; 3: 209.

31. Becker-Herman S., Meyer-Bahlburg A., Schwartz M.A., Jackson S.W., Hudkins K.L., Liu C., et al. WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. J Exp Med 2011; 208: 2033–42.

32. Balashov D., Shcherbina A., Maschan M., Trakhtman P., Skvortsova Y., Shelikhova L., et al. Single-center experience of unrelated and haploidentical stem cell transplantation with TCRalphabeta and CD19 depletion in children with primary immunodeficiency syndromes. Biol Blood Marrow Transplant 2015; 21 (11): 1955–62.